109

109 Publications Verification

Target:

Research Areas:

Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

109

Insulin solution (human)

109 Publications Verification

Cat. No.: HY-P0035A

CAS No.: 11061-68-0

Target:

Insulin Receptor

Research Areas:

Metabolic Disease

Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

74

Dapagliflozin

74 Cited Publications

Cat. No.: HY-10450

CAS No.: 461432-26-8

Purity: 99.97%

Synonyms: BMS-512148

Target:

SGLT

Research Areas:

Metabolic Disease Cancer

Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

74

Dapagliflozin ((2S)-1,2-propanediol, hydrate)

74 Cited Publications

Cat. No.: HY-10450A

CAS No.: 960404-48-2

Purity: 99.97%

Synonyms: BMS-512148 (2S)-1,2-propanediol, hydrate

Target:

SGLT

Research Areas:

Metabolic Disease Cancer

Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

43

Liraglutide

43 Cited Publications

Cat. No.: HY-P0014

CAS No.: 204656-20-2

Target:

GCGR GLP Receptor

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

32

IKK 16

32 Cited Publications

Cat. No.: HY-13687

CAS No.: 873225-46-8

Purity: 99.88%

Target:

IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related

Research Areas:

Cardiovascular Disease Inflammation/Immunology

IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC₅₀s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC₅₀s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

32

IKK 16 hydrochloride

32 Cited Publications

Cat. No.: HY-13687A

CAS No.: 1186195-62-9

Purity: 99.95%

Target:

IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related

Research Areas:

Cardiovascular Disease Inflammation/Immunology

IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC₅₀s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC₅₀s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

25

SRT 2104

25 Cited Publications

Cat. No.: HY-15262

CAS No.: 1093403-33-8

Purity: 99.00%

Target:

Sirtuin

Research Areas:

Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

SRT 2104 is a first-in-class, highly selective and brain-permeable activator of the NAD ⁺ dependent deacetylase Sirt1, increases Sirt1 protein, but shows no effect on Sirt1 mRNA. Used in the research of diabetes mellitus and Huntington’s disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

14

Enalapril

14 Cited Publications

Cat. No.: HY-B0331

CAS No.: 75847-73-3

Synonyms: MK-421

Target:

Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease

Enalapril (MK-421) is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

14

Enalapril maleate

14 Cited Publications

Cat. No.: HY-B0331A

CAS No.: 76095-16-4

Synonyms: MK-421 maleate

Target:

Angiotensin-converting Enzyme (ACE) Apoptosis Reactive Oxygen Species (ROS)

Research Areas:

Cardiovascular Disease Neurological Disease Metabolic Disease

Enalapril maleate (MK-421 maleate) is an orally active angiotensin-converting enzyme inhibitor. Enalapril maleate blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril maleate inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril maleate attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril maleate reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril maleate is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Finerenone

11 Cited Publications

Cat. No.: HY-111372

CAS No.: 1050477-31-0

Purity: 99.66%

Synonyms: BAY 94-8862

Target:

Mineralocorticoid Receptor

Research Areas:

Cardiovascular Disease Metabolic Disease

Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀ = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

8

GSK1292263

8 Cited Publications

Cat. No.: HY-12066

CAS No.: 1032823-75-8

Purity: 99.21%

Target:

GPR119

Research Areas:

Metabolic Disease Inflammation/Immunology

GSK-1292263 is an orally available GPR119 agonist with pEC₅₀s of 6.9 and 6.7 for human and rat GPR119, respectively. GSK-1292263 can be used for the research of type 2 diabetes mellitus (T2DM) .

Compare

loading...